Weight Loss

Many people on Wegovy report fewer food cravings and better control over eating, which can reduce stress around meals. Other drugs like Mysimba may also affect mood and cravings, but semaglutide’s impact on appetite tends to have the strongest indirect psychological benefit. Why psychological effects matter Weight management is never only about the body. Emotional wellbeing, self-confidence, and the stress of managing food choices all play a big role in how people experience

Clinical trials included adults up to their mid-70s, and weight loss benefits were seen across age groups. There’s limited evidence directly comparing older versus younger adults, but no major differences in effectiveness have been noted, though older people may be more sensitive to side effects. Who was included in the trials The large clinical trials of semaglutide, such as the STEP programme, included adults with overweight or obesity up to about 75 years old. This means w

Many people on Wegovy report fewer food cravings and better control over eating, which can reduce stress around meals. Other drugs like...

Wegovy is made as a biologic medicine, meaning it uses recombinant technology to produce semaglutide, a protein-based drug. Mysimba and Orlistat, by contrast, are small-molecule tablets made by chemical synthesis. These differences influence regulation and supply but not day-to-day use for patients. What makes Wegovy a biologic Wegovy (semaglutide) belongs to a group of medicines known as biologics. These are typically large, complex molecules produced in living cells using r

Both contain semaglutide and improve blood sugar by enhancing insulin release and reducing glucagon. Ozempic is specifically licensed for...

Both contain semaglutide and improve blood sugar by enhancing insulin release and reducing glucagon. Ozempic is specifically licensed for diabetes at lower doses, while Wegovy provides the same benefits at higher doses alongside more pronounced weight reduction. How semaglutide works on blood sugar Semaglutide, the active ingredient in both Wegovy and Ozempic, belongs to the GLP-1 receptor agonist family. It lowers blood sugar by stimulating insulin release when glucose level

Wegovy is made as a biologic medicine, meaning it uses recombinant technology to produce semaglutide, a protein-based drug. Mysimba and...

In many cases, Wegovy can be used as the main weight loss medicine, especially when diet and exercise alone haven’t worked. However, switching or replacing other drugs should always be guided by a clinician, as some combinations may still be appropriate depending on health needs. Wegovy as a first-choice option Since its approval by NICE in 2023, Wegovy (semaglutide 2.4 mg weekly) has become the leading option for medical weight management in the UK. Clinical evidence from th

In many cases, Wegovy can be used as the main weight loss medicine, especially when diet and exercise alone haven’t worked. However,...

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other medicines have different risks: Orlistat can cause oily stools, Mysimba may raise blood pressure, and phentermine (not used in the UK) carries cardiovascular risks. Understanding risk in context All weight-loss medicines come with benefits and risks. Doctors weigh these carefully before prescribing, taking into account a person’s health conditio

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and cardiovascular disease. Orlistat, while useful for modest weight loss, has not shown the same scale of cardiovascular benefits in large outcome studies. Two very different medicines Wegovy and Orlistat are both prescribed for weight management, but they work in completely different ways. Wegovy (semaglutide) is a GLP-1 receptor agonist that red

In the UK, coverage depends on NHS commissioning rather than insurance, and NICE now recommends Wegovy within specialist services....

In the UK, coverage depends on NHS commissioning rather than insurance, and NICE now recommends Wegovy within specialist services. Saxenda has more limited NHS use. In private healthcare or in other countries, coverage varies by insurer, but newer guidance tends to prioritise Wegovy because of its stronger results. The UK context: NHS commissioning, not insurance Unlike in the United States, where health insurance policies determine which drugs are covered, the UK relies on t

Wegovy works directly on appetite signals in the brain, helping people feel full sooner and think less about food. Other medicines act...

Wegovy works directly on appetite signals in the brain, helping people feel full sooner and think less about food. Other medicines act...

Wegovy has shown sustained weight loss of around 15% at 68 weeks, and many participants maintained benefits at two years. Qsymia (not...

Wegovy has shown sustained weight loss of around 15% at 68 weeks, and many participants maintained benefits at two years. Qsymia (not...

Trials such as STEP-1 and SELECT showed Wegovy not only reduced weight but also improved blood pressure, cholesterol, and markers of...